Akebia Q2 FY26 turns to net loss of $8.9 million; revenue falls 21.44% to $49.1 million

• Akebia posted Q2 2026 revenue of $49.1 million, down 21.44% from a year earlier, as Auryxia revenue fell to $25.5 million.
• Net loss widened to $8.9 million from net income of $0.2 million a year earlier, on lower revenue and higher expenses.
• Vafseo net product revenue rose to $21.3 million; patients on therapy climbed 41% from end-Q1 to more than 10,500.
• VOICE interim analysis showed improved safety for Vafseo versus an ESA on mortality and hospitalization (win odds 1.16; p=0.0016).
• Started a Phase 2 open-label basket trial of ebribafusp in three glomerular kidney diseases, with initial data expected in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akebia Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608051605PRIMZONEFULLFEED9804299) on August 05, 2026, and is solely responsible for the information contained therein.